Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity

Myunghoe Heo, Bit Lee, Kamakshi Sishtla, Xiang Fei, Sanha Lee, Soojun Park, Yue Yuan, Seul Lee, Sangil Kwon, Jungeun Lee, Sanghee Kim, Timothy Corson, Seung Yong Seo

Research output: Contribution to journalArticle

Abstract

Neovascular eye diseases are a major cause of blindness. Excessive angiogenesis is a feature of several conditions, including wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity. Development of novel antiangiogenic small molecules for the treatment of neovascular eye disease is essential to provide new therapeutic leads for these diseases. We have previously reported the therapeutic potential of anti-angiogenic homoisoflavanone derivatives with efficacy in retinal and choroidal neovascularization models, although these are racemic compounds due to the C3-stereogenic center in the molecules. This work presents asymmetric synthesis and structural determination of anti-angiogenic homoisoflavanones and pharmacological characterization of the stereoisomers. We describe an enantioselective synthesis of homoisoflavanones by virtue of ruthenium-catalyzed asymmetric transfer hydrogenation accompanying dynamic kinetic resolution, providing a basis for the further development of these compounds into novel experimental therapeutics for neovascular eye diseases.

Original languageEnglish (US)
Pages (from-to)9995-10011
Number of pages17
JournalJournal of Organic Chemistry
Volume84
Issue number16
DOIs
StatePublished - Aug 16 2019

Fingerprint

Hydrogenation
Molecules
Stereoisomerism
Ruthenium
Derivatives
Kinetics

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity. / Heo, Myunghoe; Lee, Bit; Sishtla, Kamakshi; Fei, Xiang; Lee, Sanha; Park, Soojun; Yuan, Yue; Lee, Seul; Kwon, Sangil; Lee, Jungeun; Kim, Sanghee; Corson, Timothy; Seo, Seung Yong.

In: Journal of Organic Chemistry, Vol. 84, No. 16, 16.08.2019, p. 9995-10011.

Research output: Contribution to journalArticle

Heo, M, Lee, B, Sishtla, K, Fei, X, Lee, S, Park, S, Yuan, Y, Lee, S, Kwon, S, Lee, J, Kim, S, Corson, T & Seo, SY 2019, 'Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity', Journal of Organic Chemistry, vol. 84, no. 16, pp. 9995-10011. https://doi.org/10.1021/acs.joc.9b01134
Heo, Myunghoe ; Lee, Bit ; Sishtla, Kamakshi ; Fei, Xiang ; Lee, Sanha ; Park, Soojun ; Yuan, Yue ; Lee, Seul ; Kwon, Sangil ; Lee, Jungeun ; Kim, Sanghee ; Corson, Timothy ; Seo, Seung Yong. / Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity. In: Journal of Organic Chemistry. 2019 ; Vol. 84, No. 16. pp. 9995-10011.
@article{57218a24f9ef48efadf45ecbde8dd309,
title = "Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity",
abstract = "Neovascular eye diseases are a major cause of blindness. Excessive angiogenesis is a feature of several conditions, including wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity. Development of novel antiangiogenic small molecules for the treatment of neovascular eye disease is essential to provide new therapeutic leads for these diseases. We have previously reported the therapeutic potential of anti-angiogenic homoisoflavanone derivatives with efficacy in retinal and choroidal neovascularization models, although these are racemic compounds due to the C3-stereogenic center in the molecules. This work presents asymmetric synthesis and structural determination of anti-angiogenic homoisoflavanones and pharmacological characterization of the stereoisomers. We describe an enantioselective synthesis of homoisoflavanones by virtue of ruthenium-catalyzed asymmetric transfer hydrogenation accompanying dynamic kinetic resolution, providing a basis for the further development of these compounds into novel experimental therapeutics for neovascular eye diseases.",
author = "Myunghoe Heo and Bit Lee and Kamakshi Sishtla and Xiang Fei and Sanha Lee and Soojun Park and Yue Yuan and Seul Lee and Sangil Kwon and Jungeun Lee and Sanghee Kim and Timothy Corson and Seo, {Seung Yong}",
year = "2019",
month = "8",
day = "16",
doi = "10.1021/acs.joc.9b01134",
language = "English (US)",
volume = "84",
pages = "9995--10011",
journal = "Journal of Organic Chemistry",
issn = "0022-3263",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity

AU - Heo, Myunghoe

AU - Lee, Bit

AU - Sishtla, Kamakshi

AU - Fei, Xiang

AU - Lee, Sanha

AU - Park, Soojun

AU - Yuan, Yue

AU - Lee, Seul

AU - Kwon, Sangil

AU - Lee, Jungeun

AU - Kim, Sanghee

AU - Corson, Timothy

AU - Seo, Seung Yong

PY - 2019/8/16

Y1 - 2019/8/16

N2 - Neovascular eye diseases are a major cause of blindness. Excessive angiogenesis is a feature of several conditions, including wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity. Development of novel antiangiogenic small molecules for the treatment of neovascular eye disease is essential to provide new therapeutic leads for these diseases. We have previously reported the therapeutic potential of anti-angiogenic homoisoflavanone derivatives with efficacy in retinal and choroidal neovascularization models, although these are racemic compounds due to the C3-stereogenic center in the molecules. This work presents asymmetric synthesis and structural determination of anti-angiogenic homoisoflavanones and pharmacological characterization of the stereoisomers. We describe an enantioselective synthesis of homoisoflavanones by virtue of ruthenium-catalyzed asymmetric transfer hydrogenation accompanying dynamic kinetic resolution, providing a basis for the further development of these compounds into novel experimental therapeutics for neovascular eye diseases.

AB - Neovascular eye diseases are a major cause of blindness. Excessive angiogenesis is a feature of several conditions, including wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity. Development of novel antiangiogenic small molecules for the treatment of neovascular eye disease is essential to provide new therapeutic leads for these diseases. We have previously reported the therapeutic potential of anti-angiogenic homoisoflavanone derivatives with efficacy in retinal and choroidal neovascularization models, although these are racemic compounds due to the C3-stereogenic center in the molecules. This work presents asymmetric synthesis and structural determination of anti-angiogenic homoisoflavanones and pharmacological characterization of the stereoisomers. We describe an enantioselective synthesis of homoisoflavanones by virtue of ruthenium-catalyzed asymmetric transfer hydrogenation accompanying dynamic kinetic resolution, providing a basis for the further development of these compounds into novel experimental therapeutics for neovascular eye diseases.

UR - http://www.scopus.com/inward/record.url?scp=85070923295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070923295&partnerID=8YFLogxK

U2 - 10.1021/acs.joc.9b01134

DO - 10.1021/acs.joc.9b01134

M3 - Article

C2 - 31381339

AN - SCOPUS:85070923295

VL - 84

SP - 9995

EP - 10011

JO - Journal of Organic Chemistry

JF - Journal of Organic Chemistry

SN - 0022-3263

IS - 16

ER -